Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) closed the day trading at $2.40 up 9.59% from the previous closing price of $2.19. In other words, the price has increased by $+0.2100 from its previous closing price. On the day, 7058993 shares were traded.
Ratios:
For a better understanding of LXRX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.58 and its Current Ratio is at 5.60. In the meantime, Its Debt-to-Equity ratio is 1.14 whereas as Long-Term Debt/Eq ratio is at 1.13.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on March 07, 2023, initiated with a Hold rating and assigned the stock a target price of $3.
On August 12, 2022, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $10.
JP Morgan Upgraded its Underweight to Neutral on January 29, 2021, while the target price for the stock was maintained at $7.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 16 ’23 when COATS LONNEL bought 90,000 shares for $1.05 per share. The transaction valued at 94,797 led to the insider holds 914,359 shares of the business.
COATS LONNEL bought 10,000 shares of LXRX for $10,100 on Nov 10 ’23. The Chief Executive Officer now owns 824,359 shares after completing the transaction at $1.01 per share. On Oct 12 ’23, another insider, DEBBANE RAYMOND, who serves as the Director of the company, bought 148,820 shares for $1.03 each. As a result, the insider paid 153,805 and bolstered with 1,340,847 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LXRX now has a Market Capitalization of 590.97M and an Enterprise Value of 527.01M. For the stock, the TTM Price-to-Sale (P/S) ratio is 488.41 while its Price-to-Book (P/B) ratio in mrq is 6.31. Its current Enterprise Value per Revenue stands at 437.71 whereas that against EBITDA is -3.22.
Stock Price History:
Over the past 52 weeks, LXRX has reached a high of $3.79, while it has fallen to a 52-week low of $0.92. The 50-Day Moving Average of the stock is 2.2986, while the 200-Day Moving Average is calculated to be 1.7351.
Shares Statistics:
Over the past 3-months, LXRX traded about 4.79M shares per day on average, while over the past 10 days, LXRX traded about 4.14M shares per day. A total of 244.92M shares are outstanding, with a floating share count of 239.51M. Insiders hold about 2.73% of the company’s shares, while institutions hold 73.92% stake in the company. Shares short for LXRX as of Mar 15, 2024 were 21.35M with a Short Ratio of 4.45, compared to 23.41M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 8.67% and a Short% of Float of 14.31%.
Earnings Estimates
Current recommendations for the stock of the company come from 3 analysts. On average, analysts expect EPS of -$0.2 for the current quarter, with a high estimate of -$0.19 and a low estimate of -$0.2, while EPS last year was -$0.17. The consensus estimate for the next quarter is -$0.18, with high estimates of -$0.15 and low estimates of -$0.21.
Analysts are recommending an EPS of between -$0.67 and -$0.75 for the fiscal current year, implying an average EPS of -$0.71. EPS for the following year is -$0.66, with 3 analysts recommending between -$0.62 and -$0.69.
Revenue Estimates
3 analysts predict $1.37M in revenue for the current quarter. It ranges from a high estimate of $2.1M to a low estimate of $1M. As of the current estimate, Lexicon Pharmaceuticals Inc’s year-ago sales were $24k, an estimated increase of 5,608.30% from the year-ago figure.
A total of 3 analysts have provided revenue estimates for LXRX’s current fiscal year. The highest revenue estimate was $40.13M, while the lowest revenue estimate was $10.8M, resulting in an average revenue estimate of $25.81M. In the same quarter a year ago, actual revenue was $1.2M, up 2,043.70% from the average estimate. Based on 3 analysts’ estimates, the company’s revenue will be $69.3M in the next fiscal year. The high estimate is $103.09M and the low estimate is $40.1M. The average revenue growth estimate for next year is up 168.50% from the average revenue estimate for this year.
